Immunotherapie du cancer par minigreffe de cellules souches hematopoietiques.

Hematologic Neoplasms/therapy; Hematopoietic Stem Cell Transplantation; Humans; Immunotherapy; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome

Abstract :

[en] Allogeneic hematopoietic stem cell transplantation (HSCT) is used for the treatment of selected haematological malignancies. Its curative potential is based on two different mechanisms, i.e. the conditioning regimen and the graft-versus-host immunologic reactions. However, because of its toxicity, it is restricted to younger and fitter patients. These observations led several groups to set up new (less toxic) transplant protocols. These transplants are called nonmyeloablative HSCT or minitransplants. These are feasible with a relatively low transplant-related mortality even in patients up to 70 years. In addition, strong anti-tumor responses are observed in several haematological malignancies.

Disciplines :

Hematology

Author, co-author :

Willems, Evelyne ; Centre Hospitalier Universitaire de Liège - CHU > Hématologie clinique

Baron, Frédéric ; Centre Hospitalier Universitaire de Liège - CHU > Hématologie clinique

Vanstraelen, Gaëtan

Frere, Pascale ; Centre Hospitalier Universitaire de Liège - CHU > Hématologie clinique

Fillet, Georges ; Centre Hospitalier Universitaire de Liège - CHU > Hématologie clinique

Beguin, Yves ; Centre Hospitalier Universitaire de Liège - CHU > Hématologie clinique

Language :

French

Title :

Immunotherapie du cancer par minigreffe de cellules souches hematopoietiques.

Alternative titles :

[en] Nonmyeloablative stem cell transplantation as cancer immunotherapy

Publication date :

2005

Journal title :

Revue Médicale Suisse

ISSN :

1660-9379

Publisher :

Medecine et Hygiène, Switzerland

Volume :

Issue :

Pages :

1973-7

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 10 February 2009

Statistics

Number of views

256 (6 by ULiège)

Number of downloads

225 (1 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenAlex citations

Bibliography

Weiden PL, Flournoy N, Thomas ED, et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic marrow grafts. N Engl J Med 1979;30:1068-73.
Weiden PL, Sullivan KM, Flournoy N, et al. Antileukemic effect of chronic graft-versus-host disease. Contribution to improved survival after allogeneic marrow transplantation. N Engl J Med 1981;304:1529-33.
Beguin Y, Collignon J, Laurent C, et al. Spontaneous complete remission and recovery of donor haemopoiesis without GVHD after relapse and apparent marrow graft rejection in poor-prognosis myelodysplastic syndrome. Br J Haematol 1996;94:507-9.
Kolb HJ, Schattenberg A, Goldman JM, et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia Blood 1995;86:2041-50.
Porter DL, Collins KH, Hardy C, et al. Treatment of relapsed leukemia after unrelated donor marrow transplantation with unrelated donor leukocyte infusions. Blood 2000;95:1214-21.
Porter DL. The graft-versus-tumor potential of allogeneic cell therapy: An update on donor leukocyte infusions and nonmyeloablative allogeneic stem cell transplantation. J Hematother Stem Cell Res 2001;10:465-80.
Alyea EP, Soiffer RJ, Canning C, et al. Toxicity and efficacy of defined doses of CD4+ donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant. Blood 1998;91:3671-80.
Mackinnon S, Papadopoulos EB, Carabasi MH, et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: Separation of graft-versus-leukemia responses from graft-versus-host disease. Blood 1995;86:1261-8.
Sykes M. Mixed chimerism and transplant tolerance. Immunity. 2001;14:417-24.
Childs R, Clave E, Contentin N, et al. Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: Full donor T-cell chimerism precedes alloimmune response. Blood 1999;94:3234-41.
McSweeney PA, Niederwieser D, Shizuru J, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: Replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001;97:3390-400.
Sorror ML, Maris MB, Storer B, et al. Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after non-myeloablative and myeloablative conditioning: Influence of pretransplant comorbidities. Blood 2004;104:961-8.
Diaconescu R, Flowers CR, Storer B, et al. Morbidity and mortality with nonmyeloablative compared to myeloablative conditioning before hematopoietic cell transplantation from HLA matched related donors. Blood 2004;104:1550-8.
Mierlcarek M, Martin PJ, Leisenring W, et al. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood 2003;102:756-62.
Couriel DR, Saliba RM, Giralt S, et al. Acute and chronic graft-versus-host disease after ablative and non-myeloablative conditioning for allogeneic hematopoietic transplantation. Biol Blood Marrow Transplant 2004;10:178-85.
Mohty M, Bay JO, Faucher C, et al. Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced intensity preparative regimen. Blood 2003;102:470-6.
Baron F, Maris MB, Sandmaier BM, et al. Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. J Clin Oncol 2005;23:1993-2003.
Frere P, Baron F, Bonnet C, et al. Infections after allogeneic haematopoietic stem cell transplantation with a non-myeloablative conditioning regimen (abstract). Bone Marrow Transplant 2005;35 (Suppl. 2):S164.
Niederwieser DW, Hegenbart U, Sandmaier BM, et al. Treatment for acute myelogenous leukemia by low dose irradiation based conditioning and hematopoietic cell transplantation from related and unrelated donors (abstract). Blood 2004;104 (Suppl. 1):840a.
Cutler CS, Lee SJ, Greenberg P, et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: Delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood 2004;104:579-85.
Scott BL, Maris M, Sandmaier B, et al. Myeloablative versus nonmyeloablative hemopoietic cell transplantation (HCT) for patients with myelodysplasia (MDS) or AML with multilineage dysplasia following MDS (tAML) (abstract). Blood 2004;104 (Suppl. 1):638a.
Doney K, Hägglund H, Leisenring W, et al. Predictive factors for outcome of allogeneic hematopoietic cell transplantation for adult acute lymphoblastic leukemia. Biol Blood Marrow Transplant 2003;9:472-81.
Martino R, Giralt S, Caballero MD, et al. Allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning in acute lymphoblastic leukemia: A feasibility study. Haematologica 2003;88:555-60.
Giralt S, Thall PF, Khouri I, et al. Melphalan and purine analog-containing preparative regimens: Reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood 2001;97:631-7.
Kottaridis PD, Milligan DW, Chopra R, et al. In vivo CAMPATH-IH prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood 2000;96:2419-25.
Bornhauser M, Thiede C, Platzbecker U, et al. Dose-reduced conditioning and allogeneic hematopoietic stem cell transplantation from unrelated donors in 42 patients. Clin Cancer Res 2001;7:2254-62.
Hallemeier C. Re: High rate of graft failure in 25 patients with chronic myelogenous leukemia conditioned with a reduced-intensity regimen of 550 cGy total body irradiation and cyclophosphamide for unrelated donor transplantation (Letter to the Editor). Biol Blood Marrow Tranplant 2004;10:726-7.
Robinson SP, Goldstone AH, Mackinnon S, et al. Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: An analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Blood 2002;100:4310-6.
Maris MB, Sandmaier BM, Storer BE, et al. Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma. Blood 2004;104:3535-42.
Dreger P, Brand R, Hansz J, et al. Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning (Review). Leukemia 2003;17:841-8.
Kroger N, Perez-Simon JA, Myint H, et al. Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma. Biol Blood Marrow Tranplant 2004;10:698-708.
Maloney DG, Molina AJ, Sahebi F, et al. Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood 2003;102:3447-54.
Childs R, Chernoff A, Contentin N, et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 2000;343:750-58.